Klichinsky, Michael
Ruella, Marco http://orcid.org/0000-0003-4301-5811
Shestova, Olga
Lu, Xueqing Maggie
Best, Andrew
Zeeman, Martha
Schmierer, Maggie
Gabrusiewicz, Konrad
Anderson, Nicholas R. http://orcid.org/0000-0001-6027-9101
Petty, Nicholas E.
Cummins, Katherine D.
Shen, Feng
Shan, Xinhe http://orcid.org/0000-0003-4976-1735
Veliz, Kimberly http://orcid.org/0000-0003-3824-1611
Blouch, Kristin
Yashiro-Ohtani, Yumi
Kenderian, Saad S.
Kim, Miriam Y.
O’Connor, Roddy S. http://orcid.org/0000-0001-5645-4544
Wallace, Stephen R.
Kozlowski, Miroslaw S.
Marchione, Dylan M. http://orcid.org/0000-0001-6941-0604
Shestov, Maksim
Garcia, Benjamin A.
June, Carl H.
Gill, Saar http://orcid.org/0000-0001-7946-7778
Funding for this research was provided by:
Penn | Perelman School of Medicine at the University of Pennsylvania | Abramson Family Cancer Research Institute
Carisma Therapeutics Inc. [Sponsored Research Agreement]
Article History
Received: 31 August 2018
Revised: 10 February 2020
Accepted: 21 February 2020
First Online: 23 March 2020
Competing interests
: M.K. and S.G. are scientific co-founders and Scientific Advisory Board members and hold equity in Carisma Therapeutics. C.J. is a member of the Scientific Advisory Board of Carisma Therapeutics. M.K., S.G. and C.J. are inventors on intellectual property related to this work. S.G. has received research funding from Carisma Therapeutics. A.B., M.Z., M.S., K.G., N.A., Y.O. and M.K. are employees of Carisma Therapeutics. Carisma Therapeutics is a company pursuing the commercial development of this technology.